Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

NCT06971614 is registered in ClinicalTrials.gov with ImmVira Pharma Co. Ltd as lead sponsor.

NCT NCT06971614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06971614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC
Lead sponsor
ImmVira Pharma Co. Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
June 9, 2025
Completion date
May 31, 2029
Enrollment
160 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nonmuscle-invasive bladder cancer